Contineum Therapeutics (NASDAQ:CTNM) Now Covered by Analysts at Stifel Nicolaus

Stifel Nicolaus initiated coverage on shares of Contineum Therapeutics (NASDAQ:CTNM) in a research report released on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $29.00 price objective on the stock.

Contineum Therapeutics Trading Down 2.5 %

NASDAQ CTNM opened at $15.60 on Tuesday. Contineum Therapeutics has a one year low of $13.90 and a one year high of $16.06.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).